DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Arbaclofen is an investigational drug.
There have been 28 clinical trials for Arbaclofen. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2011.
The most common disease conditions in clinical trials are Autism Spectrum Disorder, Child Development Disorders, Pervasive, and Autistic Disorder. The leading clinical trial sponsors are Seaside Therapeutics, Inc., Indivior Inc., and Osmotica Pharmaceutical US LLC.
Recent Clinical Trials for Arbaclofen
|Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion||Clinical Research Associates, LLC||Phase 2|
|Arbaclofen in Children and Adolescents With ASD||Hospital General Universitario Gregorio Marañon||Phase 2|
|Arbaclofen in Children and Adolescents With ASD||Inge Winter||Phase 2|